1.66

11.41% 0.17

After Hours: 1.66

Neumora Therapeutics Inc (NMRA)

Overview News Price History Option Chain Financials Why NMRA Down? Discussions Forecast

Neumora Therapeutics Inc stock is traded at $1.66, with a volume of 811.07K. It is up +11.41% in the last 24 hours and up +1.22% over the past month. Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.

Previous Close:

$1.49

Open:

$1.51

24h Volume:

811.07K

Relative Volume:

0.39

Market Cap:

$307.57M

Revenue:

Net Income/Loss:

$-222.39M

P/E Ratio:

-1.2511

EPS:

-1.3268

Net Cash Flow:

$-193.40M

1W Performance:

+1.84%

1M Performance:

+1.22%

6M Performance:

-22.07%

1Y Performance:

-29.36%

1-Day Range:

$1.5025

$1.71

1-Week Range:

$1.46

$1.71

52-Week Range:

$0.8302

$3.65

Neumora Therapeutics Inc Stock (NMRA) Company Profile

Name

Neumora Therapeutics Inc

Sector

Healthcare (1074)

Industry

Biotechnology (599)

Phone

(857) 760-0900

Address

260 ARSENAL PLACE, SUITE 1, WATERTOWN

Employee

Twitter

Next Earnings Date

2026-08-05

Latest SEC Filings

NMRA's Discussions on Twitter

Compare NMRA vs VRTX, REGN, ARGX, RVMD, ALNY

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
NMRA Neumora Therapeutics Inc	1.66	276.07M	0	-222.39M	-193.40M	-1.3268
VRTX Vertex Pharmaceuticals Inc	479.00	121.16B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	667.17	68.78B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	888.82	57.44B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	188.07	40.23B	742.00K	-1.37B	-1.07B	-7.0731
ALNY Alnylam Pharmaceuticals Inc	278.40	36.28B	4.29B	577.22M	641.34M	4.2086

Neumora Therapeutics Inc Stock (NMRA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-17-26	Upgrade	William Blair	Mkt Perform → Outperform
Jan-12-26	Initiated	Leerink Partners	Outperform
Dec-01-25	Upgrade	RBC Capital Mkts	Sector Perform → Outperform
Oct-27-25	Upgrade	Guggenheim	Neutral → Buy
Sep-16-25	Downgrade	JP Morgan	Neutral → Underweight
Apr-02-25	Downgrade	BofA Securities	Buy → Underperform
Mar-10-25	Downgrade	William Blair	Outperform → Mkt Perform
Mar-07-25	Downgrade	Guggenheim	Buy → Neutral
Mar-07-25	Downgrade	Stifel	Buy → Hold
Jan-02-25	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Nov-05-24	Downgrade	JP Morgan	Overweight → Neutral
Oct-01-24	Initiated	H.C. Wainwright	Buy
Jul-22-24	Initiated	Needham	Buy
Jul-08-24	Initiated	Mizuho	Outperform
Dec-12-23	Initiated	Deutsche Bank	Hold
Oct-10-23	Initiated	BofA Securities	Buy
Oct-10-23	Initiated	Guggenheim	Buy
Oct-10-23	Initiated	JP Morgan	Overweight
Oct-10-23	Initiated	RBC Capital Mkts	Outperform
Oct-10-23	Initiated	Stifel	Buy
Oct-10-23	Initiated	William Blair	Outperform

View All

Neumora Therapeutics Inc Stock (NMRA) Latest News

Jul 27, 2026

New toxicology data support advancement of Neumora Therapeutics’ NMRA-215 - BioWorld News

Jul 27, 2026

Neumora Therapeutics Plans Q4 IND Filing for Obesity Drug After Repeat Toxicology Study - marketscreener.com

Jul 27, 2026

Neumora reports favorable toxicology results for obesity drug - Investing.com

Jul 27, 2026

Neumora reports favorable toxicology results for obesity drug By Investing.com - Investing.com Canada

Jul 27, 2026

Neumora's Repeat NMRA-215 Rat Study Found No Unexpected Adverse Findings - Stock Titan

Jul 27, 2026